<DOC>
	<DOCNO>NCT00454636</DOCNO>
	<brief_summary>This study ass safety efficacy Xeloda , give combination standard chemotherapy regimen , first-line treatment advance and/or metastatic gastric cancer . All patient receive Xeloda combination one 4 standard chemotherapy regimen ; dose Xeloda 625mg/m2 - 1000mg/m2 bid orally , depend chemotherapy regimen use . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Combination With Chemotherapy Patients With Advanced and/or Metastatic Gastric Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; advanced metastatic gastric cancer ; Eastern Cooperative Oncology Group ( ECOG ) &lt; =2 . previous chemotherapy ( except adjuvant neoadjuvant treatment &gt; =6 month prior study ) ; evidence central nervous system ( CNS ) metastasis ; history another malignancy within last 5 year ( except successfully treat basal cell cancer skin , situ cancer cervix ) ; clinically significant cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>